{"title":"Saxagliptin: a new option for the management of type 2 diabetes","authors":"Marc Evans MRCP, MD","doi":"10.1002/fps.50","DOIUrl":null,"url":null,"abstract":"<p>Incretin-based therapies for the treatment of diabetes mellitus (T2DM) present a new approach to disease management. Over recent years, several new drugs have entered the marketplace, and NICE have recently issued guidance on how best to incorporate these new drugs into treatment regimens. In this article, Marc Evans reviews saxagliptin, a dipeptidyl peptidase-IV (DPP-IV) inhibitor, and considers its potential clinical use. Copyright © 2009 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 3","pages":"13-17"},"PeriodicalIF":0.0000,"publicationDate":"2009-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.50","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.50","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Incretin-based therapies for the treatment of diabetes mellitus (T2DM) present a new approach to disease management. Over recent years, several new drugs have entered the marketplace, and NICE have recently issued guidance on how best to incorporate these new drugs into treatment regimens. In this article, Marc Evans reviews saxagliptin, a dipeptidyl peptidase-IV (DPP-IV) inhibitor, and considers its potential clinical use. Copyright © 2009 John Wiley & Sons, Ltd.
沙格列汀:治疗2型糖尿病的新选择
以肠促胰岛素为基础的治疗糖尿病(T2DM)提供了一种新的疾病管理方法。近年来,一些新药进入市场,NICE最近发布了关于如何最好地将这些新药纳入治疗方案的指南。在本文中,Marc Evans综述了沙格列汀,一种二肽基肽酶- iv (DPP-IV)抑制剂,并考虑了其潜在的临床应用。版权所有©2009 John Wiley &儿子,有限公司
本文章由计算机程序翻译,如有差异,请以英文原文为准。